Zurich, Switzerland

Maurice Biedermann

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Hoffmann-La Roche Inc.. Active years: 2026.


% Patents Active = 100.0

 

Average Co-Inventor Count = 9.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Maurice Biedermann: Innovator in Heterocyclic Compounds

Introduction

Maurice Biedermann is a notable inventor based in Zurich, Switzerland. She has made significant contributions to the field of chemistry, particularly in the development of heterocyclic compounds. Her innovative work has led to the filing of a patent that showcases her expertise and creativity.

Latest Patents

Maurice Biedermann holds a patent for heterocyclic compounds. The invention provides new heterocyclic compounds having the general formula (I), wherein R, R, X, and Y are as defined in the patent. This patent also includes compositions featuring the compounds, processes for manufacturing them, and methods for their use. She has successfully contributed to advancing the understanding and application of these compounds in various fields.

Career Highlights

Throughout her career, Maurice has worked with prominent companies in the pharmaceutical industry, including Hoffmann-La Roche Inc. and F. Hoffmann-La Roche AG. Her experience in these organizations has allowed her to collaborate with leading experts and contribute to groundbreaking research.

Collaborations

Some of her notable coworkers include Carsten Kroll and Miroslav Kosar. Their collaborative efforts have further enhanced the impact of her work in the field of chemistry.

Conclusion

Maurice Biedermann's contributions to the development of heterocyclic compounds exemplify her innovative spirit and dedication to scientific advancement. Her patent and collaborations reflect her significant role in the field, making her a noteworthy inventor in the industry.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…